Actively Recruiting
Effect of Acute ObeEnd Exposure on Factors Regulating Appetite
Led by Concordia University, Montreal · Updated on 2024-07-05
30
Participants Needed
1
Research Sites
38 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
n Canada, over 60% of adults are classified as overweight and obese resulting in a public health crisis including increasing health care costs and negatively impacting the well-being of many Canadians. To overcome these barriers, the ObeEnd device, manufactured by WAT Medical Enterprise, is a new and innovative wellness technology that uses electrical pulses to stimulate acupressure point PC6 to help control appetite. PC6 stimulation could potentially modulate appetite and restore gastric dysfunction, which are important factors that contribute to obesity. If PC6 electrostimulation facilitates the normalization of appetite and restoration of gastric dysfunction in those with obesity, then the device could be a potentially helpful aid to weight loss. To measure the change of appetite hormones and enzymes related to appetite regulation after using the ObeEnd device. The investigators hypothesize that, compared to placebo, acute electrostimulation of PC6 an acupuncture spot on the wrist for a 1 hour period will result in changes in enterogastric hormones in a direction that decreases appetite. This study will provide the first evidence of the acute effects of electrostimulation at PC6 on factors affecting body weight regulation providing insight into the utility of the ObeEnd device for weight control.
CONDITIONS
Official Title
Effect of Acute ObeEnd Exposure on Factors Regulating Appetite
Who Can Participate
Eligibility Criteria
You may qualify if you...
- People with obesity (BMI>30kg/m2)
- Generally healthy
- Premenopausal females
You will not qualify if you...
- Past (<1 year) or present use of nicotine products
- History of chronic disease or metabolic conditions
- Females who are pregnant, less than 6 months postpartum, or breastfeeding
- Diagnosed hepatic disease, renal impairment, uncontrolled hypothyroidism
- Use of any medications that may affect study outcomes (e.g. hormone replacement therapy)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Concordia University
Montreal, Quebec, Canada, H4B1R6
Actively Recruiting
Research Team
S
Sylvia Santosa, PhD
CONTACT
A
Anjalee I Wanasinghee
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here